Crinetics Pharmaceuticals gains FDA approval for PALSONIFY, targeting key unmet needs in Acromegaly. Click here to read my ...

The U.S. Food and Drug Administration approved Crinetics Pharmaceuticals' drug to treat a rare hormonal disorder on Thursday, ...

The regulatory greenlight was backed by two Phase III trials that showed normalized growth hormone levels in patients with ...

Paltusotine (Palsonify; Crinetics), a novel nonpeptide somatostatin receptor type 2 nonpeptide (SST2) agonist, was approved by the FDA for the treatment of acromegaly in adults who had an inadequate ...

The Food and Drug Administration (FDA) has approved Palsonify ™ (paltusotine) for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an ...

What Everyday Athletes Should Know Milk has long been touted as a "growth food," and science continues to back up its role in ...

PALSONIFY™ (paltusotine) INDICATION: PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom ...

Viridian Therapeutics (VRDN) offers a differentiated next-gen therapy for Thyroid Eye Disease, targeting a large, underpenetrated market dominated ...

Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 ...

Groundbreaking research sheds light on why women are disproportionately affected by dementia — and points to promising new ...

Want to live to 100? Well, here’s some news that might make your pizza-loving heart skip a beat (and not in a good way).

What a New Study Reveals For years, public debates around nutrition have often painted animal protein as a potenti ...